Other languages Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
1.61 ^USD	-1.23%		+7.33%	-16.58%

23/04	Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	MT
23/04	Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	23/04
Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/04
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss	06/02
Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME	12/12
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Sector Update: Health Care Stocks Rising Late Afternoon	11/11
Sector Update: Health Care	11/11
Unity Biotechnology Agrees to Exercise Warrants for $4.38 Million in Gross Proceeds; Shares Fall	11/11
UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration	27/23/27
Unity Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09
Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema	21/23/21
Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10
Unity Biotechnology, Inc. Announces Positive 48-Week Results from Phase 2 Bold Study of UBX1325 in Patients with Diabetic Macular Edema	24/23/24
Unity Biotechnology, Inc. Announces Resignation of Jamie Dananberg as Chief Medical Officer, Effective April 30, 2023	12/23/12
Top Midday Decliners	27/23/27
Unity Biotechnology's Study of UBX1325 for Wet Age-Related Macular Degeneration Failed to Meet Non-Inferiority Threshold	27/23/27
Unity Biotechnology, Inc. Announces Results from Part A of the Phase 2 Envision Study	27/23/27
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	16/23/16
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	16/23/16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Unity Biotechnology, Inc.

Equities

UBX

US91381U2006

Other languages

Filters